Grant of Interim Extension of the Term of U.S. Patent No. 7,179,464; Benralizumab, 33485 [2017-15249]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 138 / Thursday, July 20, 2017 / Notices
Dated: July 17, 2017.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
[FR Doc. 2017–15262 Filed 7–19–17; 8:45 am]
RIN 0648–XF560
BILLING CODE 3510–22–P
New England Fishery Management
Council; Public Meeting
DEPARTMENT OF COMMERCE
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
AGENCY:
ACTION:
Notice; public meeting.
The New England Fishery
Management Council (Council) is
scheduling a public meeting of its
Observer Policy Committee to consider
actions affecting New England fisheries
in the exclusive economic zone (EEZ).
Recommendations from this group will
be brought to the full Council for formal
consideration and action, if appropriate.
SUMMARY:
This meeting will be held on
Thursday, August 3, 2017 at 9 a.m.
DATES:
The meeting will be held at
the Hilton Garden Inn, 100 Boardman
Street, Boston, MA 02128; telephone:
(617) 567–6789.
Council address: New England
Fishery Management Council, 50 Water
Street, Mill 2, Newburyport, MA 01950.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Thomas A. Nies, Executive Director,
New England Fishery Management
Council; telephone: (978) 465–0492.
SUPPLEMENTARY INFORMATION:
Agenda
The Committee will discuss recent
and planned work related to 2017
priorities, including development of a
policy for monitoring commercial
fisheries to address multiple
information needs and a strategic
approach to bycatch monitoring, and
recommend appropriate next steps. The
Committee will also discuss priorities
for 2018; other business will be
discussed as necessary.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Special Accommodations
This meeting is physically accessible
to people with disabilities. This meeting
will be recorded. Consistent with 16
U.S.C. 1852, a copy of the recording is
available upon request. Requests for
sign language interpretation or other
auxiliary aids should be directed to
Thomas A. Nies, Executive Director, at
(978) 465–0492, at least 5 days prior to
the meeting date.
Authority: 16 U.S.C. 1801 et seq.
VerDate Sep<11>2014
18:50 Jul 19, 2017
Jkt 241001
Patent and Trademark Office
[Docket No.: PTO–P–2017–0029]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,179,464;
Benralizumab
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting interim extension for a oneyear interim extension of the term of
U.S. Patent No. 7,179,464.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On June 30, 2017, Kyowa Hakko Kirin
Co., Ltd., the patent owner of record,
timely filed an application under 35
U.S.C. 156(d)(5) for an interim extension
of the term of U.S. Patent No. 7,179,464.
The patent claims methods of using the
human biological product
benralizumab. The application for
patent term extension indicates that a
Biological License Application (BLA)
761070 was submitted to the Food and
Drug Administration (FDA) on
November 16, 2016.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
SUMMARY:
PO 00000
Frm 00010
Fmt 4703
Sfmt 4703
33485
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the original
expiration date of the patent, July 21,
2017, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,179,464 is granted for a period of one
year from the original expiration date of
the patent.
Dated: July 17, 2017.
Robert Bahr,
Deputy Commissioner for Patent Examination
Policy, United States Patent and Trademark
Office.
[FR Doc. 2017–15249 Filed 7–19–17; 8:45 am]
BILLING CODE 3510–16–P
CORPORATION FOR NATIONAL AND
COMMUNITY SERVICE
Agency Information Collection
Activities; Submission to the Office of
Management and Budget for Review
and Approval; Comment Request;
CNCS Grant Application; Proposed
Information Collection; Comment
Request
Corporation for National and
Community Service.
ACTION: Notice.
AGENCY:
The Corporation for National
and Community Service (CNCS) has
submitted a public information
collection request (ICR) entitled CNCS
Grant Application for review and
approval in accordance with the
Paperwork Reduction Act of 1995, Pub.
L. 104–13, (44 U.S.C. Chapter 35).
Copies of this ICR, with applicable
supporting documentation, may be
obtained by calling the Corporation for
National and Community Service, Amy
Borgstrom, at 202–606–6930 or email to
aborgstrom@cns.gov. Individuals who
use a telecommunications device for the
deaf (TTY–TDD) may call 1–800–833–
3722 between 8:00 a.m. and 8:00 p.m.
Eastern Time, Monday through Friday.
DATES: Comments may be submitted,
identified by the title of the information
collection activity, within August 21,
2017.
SUMMARY:
Comments may be
submitted, identified by the title of the
information collection activity, to the
Office of Information and Regulatory
Affairs, Attn: Ms. Sharon Mar, OMB
Desk Officer for the Corporation for
National and Community Service, by
any of the following two methods
within 30 days from the date of
publication in the Federal Register:
ADDRESSES:
E:\FR\FM\20JYN1.SGM
20JYN1
]]>Agencies
[Federal Register Volume 82, Number 138 (Thursday, July 20, 2017)]
[Notices]
[Page 33485]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-15249]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No.: PTO-P-2017-0029]
Grant of Interim Extension of the Term of U.S. Patent No.
7,179,464; Benralizumab
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting interim extension for a one-year interim extension of
the term of U.S. Patent No. 7,179,464.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On June 30, 2017, Kyowa Hakko Kirin Co., Ltd., the patent owner of
record, timely filed an application under 35 U.S.C. 156(d)(5) for an
interim extension of the term of U.S. Patent No. 7,179,464. The patent
claims methods of using the human biological product benralizumab. The
application for patent term extension indicates that a Biological
License Application (BLA) 761070 was submitted to the Food and Drug
Administration (FDA) on November 16, 2016.
Review of the patent term extension application indicates that,
except for permission to market or use the product commercially, the
subject patent would be eligible for an extension of the patent term
under 35 U.S.C. 156, and that the patent should be extended for one
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory
review period will continue beyond the original expiration date of the
patent, July 21, 2017, interim extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 7,179,464 is granted for a period of one year from the
original expiration date of the patent.
Dated: July 17, 2017.
Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent
and Trademark Office.
[FR Doc. 2017-15249 Filed 7-19-17; 8:45 am]
BILLING CODE 3510-16-P
